Vitamin D Repletion for Adults with Deficiency
Recommended Repletion Protocol
For adults with documented vitamin D deficiency (serum 25-hydroxyvitamin D <20 ng/mL), administer cholecalciferol (vitamin D₃) 50,000 IU once weekly for 8–12 weeks, followed by maintenance therapy of 800–2,000 IU daily to sustain levels ≥30 ng/mL. 1
Loading Phase (Initial Correction)
- Standard regimen: Cholecalciferol 50,000 IU once weekly for 8 weeks if baseline 25(OH)D is 10–20 ng/mL 1, 2
- Extended regimen: Cholecalciferol 50,000 IU once weekly for 12 weeks if baseline 25(OH)D is <10 ng/mL (severe deficiency) 1
- Alternative formulation: Ergocalciferol (vitamin D₂) 50,000 IU weekly for 8 weeks is acceptable, though cholecalciferol is preferred because it maintains serum concentrations longer and has superior bioavailability 1, 2
The cumulative dose over 8–12 weeks (400,000–600,000 IU) reliably raises serum 25(OH)D by approximately 40–70 ng/mL in most patients, bringing levels from deficiency into the target range of ≥30 ng/mL 1.
Maintenance Phase (After Achieving Target)
- Standard maintenance: 800–1,000 IU cholecalciferol daily for most adults 1, 2
- Higher-risk populations: 2,000 IU daily for patients with obesity, malabsorption, dark skin pigmentation, limited sun exposure, or chronic kidney disease stages 3–4 1, 3
- Alternative intermittent dosing: 50,000 IU cholecalciferol once monthly (equivalent to ~1,600 IU daily) is acceptable for patients who prefer less frequent dosing 1
Target Serum Levels
- Minimum target: ≥30 ng/mL (75 nmol/L) for optimal musculoskeletal health, fracture prevention, and fall reduction 1, 4
- Optimal range: 30–44 ng/mL provides maximal health benefits; levels above 50 ng/mL offer no additional advantage 1, 4
- Upper safety limit: 100 ng/mL; toxicity is rare below this threshold 1, 4
Monitoring Protocol
Timing of Follow-Up Testing
- Re-check serum 25(OH)D after 3 months of supplementation to allow levels to plateau and accurately reflect treatment response 1, 3
- Testing earlier than 3 months is discouraged because vitamin D has a long half-life and serum concentrations need adequate time to stabilize 1
- If using intermittent dosing (weekly or monthly), measure levels immediately before the next scheduled dose 1
Long-Term Monitoring
- Once stable levels ≥30 ng/mL are achieved, annual monitoring is sufficient 1
- For patients with chronic kidney disease, check serum calcium and phosphorus every 3 months during supplementation 1
Essential Co-Interventions
Calcium Supplementation
- Ensure total calcium intake of 1,000–1,200 mg daily from diet plus supplements if needed 1, 3
- Calcium supplements should be taken in divided doses of no more than 600 mg at once for optimal absorption 1
- Adequate calcium is necessary for vitamin D to exert its full bone-protective effects 1
Special Populations Requiring Modified Approaches
Malabsorption Syndromes
- Post-bariatric surgery (Roux-en-Y, biliopancreatic diversion): Intramuscular cholecalciferol 50,000 IU is the preferred route because oral absorption remains markedly impaired; IM dosing achieves 58% higher serum levels than high-dose oral therapy 1
- When IM is unavailable: Escalate oral cholecalciferol to 4,000–5,000 IU daily for 2 months, or 50,000 IU 1–3 times weekly 1
- Minimum maintenance after bariatric surgery: 2,000 IU daily to prevent recurrent deficiency 1
- Other malabsorptive conditions (inflammatory bowel disease, pancreatic insufficiency, short bowel syndrome, untreated celiac disease): Consider IM cholecalciferol 50,000 IU if oral supplementation fails 1
Chronic Kidney Disease (CKD Stages 3–4)
- Use standard nutritional vitamin D (cholecalciferol or ergocalciferol) with the same loading and maintenance regimens as the general population 1
- Do not use active vitamin D analogs (calcitriol, alfacalcidol, doxercalciferol, paricalcitol) to treat nutritional deficiency, as they bypass normal regulatory mechanisms and markedly increase hypercalcemia risk 1
- Monitor serum calcium and phosphorus every 3 months; discontinue all vitamin D immediately if calcium exceeds 10.2 mg/dL (2.54 mmol/L) 1
Elderly Adults (≥65 Years)
- Minimum maintenance dose: 800 IU daily, though 700–1,000 IU daily more effectively reduces fall and fracture risk 1
- Institutionalized elderly may be started on 800 IU daily without baseline testing given the high prevalence of deficiency 1, 3
Pregnancy
- Add 600 IU daily to baseline needs, achieving a total of 1,000–1,200 IU daily 3
- Avoid single bolus doses >25,000 IU during pregnancy 5
Safety Considerations and Contraindications
Safe Dosing Limits
- Daily doses up to 4,000 IU are considered completely safe for long-term use in adults 1, 3
- Limited evidence supports doses up to 10,000 IU daily for several months without adverse effects 1, 3
- Toxicity typically occurs only with prolonged daily doses >10,000 IU or serum 25(OH)D levels >100 ng/mL 1, 4
Monitoring for Toxicity
- Clinical manifestations: Hypercalcemia, hyperphosphatemia, suppressed parathyroid hormone, hypercalciuria 1
- Check serum calcium and phosphorus every 3 months during high-dose therapy 1
- Discontinue all vitamin D immediately if serum calcium exceeds 10.2 mg/dL (2.54 mmol/L) 1
Contraindicated Practices
- Do not use active vitamin D analogs (calcitriol, alfacalcidol, doxercalciferol, paricalcitol) for nutritional deficiency; they are reserved for advanced CKD with impaired 1α-hydroxylase activity 1
- Avoid single annual mega-doses (≥300,000 IU), which have been associated with increased falls and fractures in clinical trials 1, 3
Common Pitfalls and How to Avoid Them
Inadequate Dosing
- Pitfall: Using 600–800 IU daily as initial therapy for deficiency; this dose is insufficient to correct deficiency and would take many weeks to normalize levels 1
- Solution: Always use the loading dose regimen (50,000 IU weekly for 8–12 weeks) for documented deficiency (<20 ng/mL) 1
Premature Laboratory Testing
- Pitfall: Re-checking 25(OH)D levels before 3 months; this does not reflect true steady-state levels and may lead to inappropriate dose adjustments 1
- Solution: Wait at least 3 months after initiating or adjusting therapy before re-measuring 1, 3
Ignoring Calcium Co-Supplementation
- Pitfall: Providing vitamin D without ensuring adequate calcium intake; vitamin D alone is less effective for bone health 1
- Solution: Verify total calcium intake is 1,000–1,200 mg daily from all sources 1, 3
Using Vitamin D₂ for Intermittent Dosing
- Pitfall: Prescribing ergocalciferol (D₂) for weekly or monthly regimens; D₂ maintains serum levels for shorter periods than D₃ 1
- Solution: Prefer cholecalciferol (D₃) for all intermittent dosing schedules 1
Failure to Identify Malabsorption
- Pitfall: Continuing oral supplementation in patients with persistent deficiency despite adequate dosing; this suggests unrecognized malabsorption 1
- Solution: If 25(OH)D remains <20 ng/mL after 3 months of standard therapy, investigate for malabsorption (post-bariatric surgery, inflammatory bowel disease, pancreatic insufficiency, celiac disease) and consider IM administration 1
Misuse of Active Vitamin D Analogs
- Pitfall: Prescribing calcitriol or other active analogs for nutritional deficiency; these do not correct 25(OH)D levels and dramatically increase hypercalcemia risk 1
- Solution: Reserve active analogs exclusively for advanced CKD with PTH >300 pg/mL despite vitamin D repletion 1
Expected Clinical Outcomes
- Achieving serum 25(OH)D ≥30 ng/mL reduces non-vertebral fractures by ~20% and hip fractures by ~18% 1
- Fall risk is lowered by approximately 19% with adequate supplementation 1
- Anti-fracture efficacy begins at 30 ng/mL and continues to improve up to 44 ng/mL 1
- Anti-fall efficacy starts at 24 ng/mL but is maximized at ≥30 ng/mL 1